Want to see AU:MVP full AI Analyst Report?
MVP Stock Chart & Stats
AU$0.50
-AU$0.02(-4.00%)
At close: 4:00 PM EDT
AU$0.50
-AU$0.02(-4.00%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$0.77
Previous CloseN/A
Volume529.07K
Average Volume (3M)118.82K
Market Cap
AU$51.26M
Enterprise ValueAU$47.48
Total Cash (Recent Filing)AU$16.88M
Total Debt (Recent Filing)AU$3.34M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Aug 20, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding112,658,325
10 Day Avg. Volume79,692
30 Day Avg. Volume118,816
Financial Highlights & Ratios
PEG Ratio-6.10
Price to Book (P/B)1.17
Price to Sales (P/S)1.65
P/FCF Ratio-132.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$47.45M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA 75%+ gross margin indicates durable production and pricing advantages for core products like Penthrox. High product-level margins provide structural buffer versus SG&A rises, support reinvestment in commercial expansion, and improve the company's ability to absorb short-term cost or volume shocks over the next 2–6 months.
Low Financial LeverageVery low debt-to-equity gives the company financial flexibility to fund commercialization, regulatory work, or partner transitions without immediate refinancing risk. This balance-sheet strength supports investment in market access and cushions operations if respiratory demand remains soft in coming quarters.
Regulatory / Pediatric ProgressPublished pediatric data and near-term Europe approvals materially expand the addressable market (age 6+), enable ambulance and pediatric usage, and support broader label adoption. This regulatory progress is a durable, structural driver of demand and partner uptake over the medium term.
Bears Say
Weak ProfitabilityExtremely low EBIT and net margins limit the company’s ability to convert revenue into retained earnings. This structural profitability weakness constrains internal funding for marketing, evidence generation and expansion, and increases sensitivity to FX, pricing or cost shocks across the next several quarters.
Deteriorating Cash GenerationSharp free-cash-flow deterioration and negative operating cash flow reduce liquidity runway for commercial investment and increase reliance on existing cash or external capital. Persistently weak cash conversion raises execution risk for launches, partner programs and tender participation over 2–6 months.
Respiratory Segment Weakness (US)A material and persistent decline in respiratory revenues, driven by a ~16% U.S. fall, reduces revenue diversification and amplifies earnings volatility. Given the cited expectation that softness will persist, this structural drag will weigh on group results and cash generation in the near-to-medium term.
Medical Developments International Limited News
MVP FAQ
What was Medical Developments International Limited’s price range in the past 12 months?
Medical Developments International Limited lowest share price was AU$0.36 and its highest was AU$0.77 in the past 12 months.
What is Medical Developments International Limited’s market cap?
Medical Developments International Limited’s market cap is AU$51.26M.
When is Medical Developments International Limited’s upcoming earnings report date?
Medical Developments International Limited’s upcoming earnings report date is Aug 20, 2026 which is in 19 days.
How were Medical Developments International Limited’s earnings last quarter?
Medical Developments International Limited released its earnings results on Feb 18, 2026. The company reported -AU$0.002 earnings per share for the quarter, beating the consensus estimate of -AU$0.014 by AU$0.012.
Is Medical Developments International Limited overvalued?
According to Wall Street analysts Medical Developments International Limited’s price is currently Undervalued.
Does Medical Developments International Limited pay dividends?
Medical Developments International Limited pays a Semiannually dividend of AU$0.019 which represents an annual dividend yield of N/A. See more information on Medical Developments International Limited dividends here
What is Medical Developments International Limited’s EPS estimate?
Medical Developments International Limited’s EPS estimate is >-0.01.
How many shares outstanding does Medical Developments International Limited have?
Medical Developments International Limited has 112,658,325 shares outstanding.
What happened to Medical Developments International Limited’s price movement after its last earnings report?
Medical Developments International Limited reported an EPS of -AU$0.002 in its last earnings report, beating expectations of -AU$0.014. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Medical Developments International Limited?
Currently, no hedge funds are holding shares in AU:MVP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medical Developments International Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (100.00% Upside)
AU$1.00 (100.00% Upside)
Blogger Sentiment
Bullish
AU:MVP Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.70%
Trailing 12-Months
Company Description
Medical Developments International Limited
Medical Developments International Limited (MDIL) specializes in the development and provision of essential emergency medical solutions, serving global markets including Australia, Europe, and the United States. The company's operations are divided into two primary segments: Pain Management and Respiratory care. Among its key offerings is Penthrox, a product specifically formulated for rapid pain relief in acute trauma and emergency situations. Within the respiratory segment, MDIL supplies equipment designed to assist individuals with conditions like asthma and chronic obstructive pulmonary disease (COPD). Additionally, its comprehensive portfolio features a diverse array of medical devices, encompassing items such as CPR face shields and masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, oxygen resuscitation kits, and various oxygen therapy and resuscitation apparatus. Established in 2003, the company maintains its headquarters in Scoresby, Australia.
MVP Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(100.00% Upside)
Technical Analysis
Cann Group
―
Epsilon Healthcare Limited
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―